

#### SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number				
Administrative info	Administrative information						
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1				
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4				
	2b	All items from the World Health Organization Trial Registration Data Set	N/A				
Protocol version	3	Date and version identifier	17				
Funding	4	Sources and types of financial, material, and other support	3 + 23				
Roles and	5a	Names, affiliations, and roles of protocol contributors	1 + 17-18				
responsibilities	5b	Name and contact information for the trial sponsor	17				
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A				
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A				

### Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	
	6b	Explanation for choice of comparators	9 + 11 – 12
Objectives	7	Specific objectives or hypotheses	9
Trial design	8	Description of trial design including type of trial (e.g., parallel group, crossover, factorial, single group), allocation ratio, and framework (e.g., superiority, equivalence, noninferiority, exploratory)	9 – 10
Methods: Participa	nts, int	erventions, and outcomes	
Study setting	9	Description of study settings (e.g., community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	10
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (e.g., surgeons, psychotherapists)	10 – 12
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6 – 8
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (e.g., drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (e.g., drug tablet return, laboratory tests)	N/A
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (e.g., systolic blood pressure), analysis metric (e.g., change from baseline, final value, time to event), method of aggregation (e.g., median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6 + 11 – 12
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	11

## Methods: Assignment of interventions (for controlled trials)

### Allocation:

Sequence generation	16a	Method of generating the allocation sequence (e.g., computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (e.g., blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (e.g., central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	10
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9 + 11
Blinding (masking)	17a	Who will be blinded after assignment to interventions (e.g., trial participants, care providers, outcome assessors, data analysts), and how	8 – 9
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A

# Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (e.g., duplicate measurements, training of assessors) and a description of study instruments (e.g., questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13 – 14
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	The study design and the associated regular mailing of questionnaires will encourage retention in the study and ensure regular follow-up. Study participants may also contact the study team at any time by telephone or Email. See also page 11.
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (e.g., double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13 – 14
	20b	Methods for any additional analyses (e.g., subgroup and adjusted analyses)	14 – 15
	20c	Definition of analysis population relating to protocol non-adherence (e.g., as randomised analysis), and any statistical methods to handle missing data (e.g., multiple imputation)	Intention-to-treat (ITT) analysis will be performed to include all participants as originally allocated. Additionally, depending on available resources, double data entry of questionnaires will be performed.

**Methods: Monitoring** 

Data monitoring

Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol.

Alternatively, an explanation of why a DMC is not needed

This study does not have a Data Monitoring Committee (DMC). The decision to forgo a DMC is based the nature of the trial, which does

This study does not have a Data
Monitoring Committee (DMC). The
decision to forgo a DMC is based on
the nature of the trial, which does not
require interim safety or efficacy
analysis that would necessitate
independent oversight. All participating
scientists have declared their
competing interests, which are
transparently disclosed and will be
managed according to the study's
conflict-of-interest policy.

21b Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial

No interim analyses or formal stopping guidelines are planned for this study, as it does not involve high-risk procedures. The primary concern related to potential harm is time constraints for participants and caregivers when completing the questionnaires. The trial is expected to proceed as planned unless significant issues with data collection or participant burden arise, which will be addressed by the study investigators. No external party will be responsible for making decisions regarding the early termination of the trial.

Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported	Given that the study does not involve high-
		adverse events and other unintended effects of trial interventions or trial conduct	risk procedures, no serious adverse events
			are anticipated. The main potential
			unintended effect is participant burden,
			specifically time constraints caused by the
			completion of questionnaires. Participants
			will be informed that they can discontinue
			participation at any time. Any reports of
			undue burden or other negative experiences
			will be documented, assessed by the study
			team, and addressed accordingly.
			Procedures for managing and reporting
			such instances will follow standard ethical
			guidelines.
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A
Ethics and dissemi	ination		
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	The REC at both study sites has approved the project. See page 15.

Protocol amendments	25	Plans for communicating important protocol modifications (e.g., changes to eligibility criteria, outcomes, analyses) to relevant parties (e.g., investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	Any important modifications to the trial protocol, such as changes to eligibility criteria, outcomes, or analyses, will be promptly communicated to all relevant parties. This includes the investigators, Research Ethics Committees (REC), the sponsor, trial participants, and regulatory authorities. Amendments will also be updated in trial registries and communicated to journals if applicable, ensuring transparency and compliance with Good Clinical Practice (GCP) guidelines.
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Informed consent or the assent of potential study participants or authorised representatives is obtained by the members of the study teams responsible for enrolment at the two study sites. See also page 15.
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	11 – 15
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	17-18

Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	In accordance with the requirements set by the study's sponsor, access to the final trial dataset will be granted to all interested parties after the study is completed. The dataset will be anonymized to ensure participant confidentiality. There are no contractual agreements that limit access to the investigators or any other parties.
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	Given the nature of the study, no ancillary or post-trial care is required. The expected risk to participants is minimal, primarily limited to potential time-related burdens. In the unlikely event that a participant experiences harm directly related to their participation in the study, no formal compensation provisions have been established, as no significant physical or psychological harm is anticipated.
Dissemination policy	/ 31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (e.g., via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15

	31b	Authorship eligibility guidelines and any intended use of professional writers  Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	Authorship eligibility will follow the guidelines established by the International Committee of Medical Journal Editors (ICMJE). Individuals who have made substantial contributions to the conception, design, data collection, analysis, or interpretation of the study, as well as those involved in drafting or critically revising the manuscript, will be eligible for authorship. No professional writers will be employed for this study; all writing will be conducted by the investigators and collaborators.  In compliance with the requirements of the study's sponsor, the full study protocol, participant-level dataset (with appropriate anonymization to protect participant privacy), and the statistical code used for analysis will be made publicly accessible upon the completion of the study. Further details regarding access will be provided in the final publication and on the study's dedicated website.
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	/
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A

<sup>\*</sup>It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.